On November 13, 2019 Skyhawk Therapeutics, Inc. (Skyhawk), reported that it has reached a second global strategic collaboration agreement with a subsidiary of Celgene Corporation (NASDAQ: CELG ) (Press release, Skyhawk Therapeutics, NOV 13, 2019, View Source [SID1234551230]). This new agreement is made after the June 2018 collaboration between the two companies and focuses on relevant targets in the field of autoimmune disorders, oncology and immunooncology, thus revalidating the patented SkySTAR TM technology platformfrom Skyhawk. The scope of this collaboration allows the parties to systematically examine a series of targets that have been clinically validated or that are associated at a high level with the genetic basis of the disease, but that have been considered resistant to drugs by conventional based treatments of small molecules.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the collaboration agreement, Skyhawk grants Celgene the option to grant exclusive licenses of intellectual property rights worldwide to pharmacological candidates discovered and developed under the auspices of the collaboration agreement and aimed at the targets of the program. In the event that Celgene decides to make use of this option, Celgene will be responsible for its development and commercialization.
"Our impressive advances to date in relation to the targets that our collaboration that took place in 2018 includes have led Celgene to sign this new agreement focused on targets that go beyond neurology," said Bill Haney , co-founder and CEO from Skyhawk Therapeutics. "This is further proof of the capacity of our SkySTAR TM technology platformto quickly identify niches where to apply the drugs and the unique chemical matter to correct the incorrect splicing of RNA, and that can lead to new treatment options for patients. We look forward to seeing the progress of the programs in line with this new collaboration and the potential to offer new treatment options to patients with unmet medical needs. "
"The rapid and remarkable progress made by the Skyhawk team shows us the exclusive advantages of the SkySTAR TM platform and has led us to expand our relationship. We see the Skyhawk platform as a revolutionary and key technology that supports the portfolio of disease treatments autoimmune, oncological and immuno-oncology of the company that we are today and that which we have set ourselves to become, "said Rupert Vessey , MA, BM, B.Ch., FRCP, D.Phil., president of Research and Initial Development of Celgene Corporation